H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on BiomX (PHGE) today and set a price target of $20.00. The company’s shares closed last Wednesday at $6.12.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 33.6% and a 55.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BiomX with a $22.50 average price target, a 251.6% upside from current levels. In a report issued on May 24, Chardan Capital also reiterated a Buy rating on the stock with a $28.00 price target.
See today’s analyst top recommended stocks >>
Based on BiomX’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $9.14 million. In comparison, last year the company had a GAAP net loss of $292.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BiomX Ltd engages in developing bacteriophage-based therapies for the treatment and prevention of diseases stemming from dysbiosis of the microbiome. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
Read More on PHGE:
